Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/21/2020 09/22/2020 09/23/2020 09/24/2020 09/25/2020 Date
434.95(c) 437.2(c) 445.5(c) 437.3(c) 439.4(c) Last
2 181 273 1 851 172 2 507 078 2 396 007 1 562 471 Volume
-0.01% +0.52% +1.90% -1.84% +0.48% Change
More quotes
Financials
Sales 2020 128 B 19 942 M 19 942 M
Net income 2020 41 699 M 6 519 M 6 519 M
Net cash position 2020 11 683 M 1 826 M 1 826 M
P/E ratio 2020 24,6x
Yield 2020 2,04%
Sales 2021 136 B 21 271 M 21 271 M
Net income 2021 45 794 M 7 159 M 7 159 M
Net cash position 2021 14 902 M 2 330 M 2 330 M
P/E ratio 2021 21,8x
Yield 2021 2,22%
Capitalization 1 022 B 159 B 160 B
EV / Sales 2020 7,92x
EV / Sales 2021 7,40x
Nbr of Employees 43 526
Free-Float 68,7%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
09/25NOVO NORDISK : UBS reiterates its Neutral rating
MD
09/23NOVO NORDISK A/S : - Switching to investigational once-weekly insulin icodec fro..
AQ
09/22NOVO NORDISK A/S : Switching to investigational once-weekly insulin icodec from ..
PU
09/21NOVO NORDISK A/S : launches new 100% renewable power target for suppliers
AQ
09/21NOVO NORDISK A/S : launches new 100% renewable power target for suppliers
PU
09/14European healthcare stocks hit by Trump drug order
RE
09/14NOVO NORDISK A/S : – Share repurchase programme
AQ
09/01NOVO NORDISK A/S : insulin production line launches in Iran
AQ
08/31NOVO NORDISK A/S : – Share repurchase programme
AQ
08/26NOVO NORDISK A/S : Disclosure of transaction data related to Novo Nordisk's shar..
PU
08/25NOVO NORDISK A/S : Karolinska Institutet, St. Erik Eye Hospital and Novo Nordisk..
AQ
08/20NOVO NORDISK A/S : Q2 2020 conference call presentation
PU
08/20NOVO NORDISK A/S : Q2 2020 London presentation
PU
08/18NOVO NORDISK : UBS sticks Neutral
MD
08/17NOVO NORDISK A/S : Disclosure of transaction data
PU
More news
News in other languages on NOVO NORDISK A/S
09/25NOVO NORDISK : UBS conserve son opinion neutre
09/25UBS belässt Novo Nordisk auf 'Neutral' - Ziel 415 Kronen
09/25TOUR DU MONDE DES INDICES : †Tesla-dépendance et irréductibles danois
09/24NOVO NORDISK : une étude sur les maladies cardiovasculaires
09/21BOURSE : Chassez la distanciation sociale, elle revient au galop
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 445,67 DKK
Last Close Price 439,40 DKK
Spread / Highest target 19,5%
Spread / Average Target 1,43%
Spread / Lowest Target -30,6%
EPS Revisions
Managers
NameTitle
Lars Fruergaard JÝrgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S13.64%159 466
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402